


9.45 - 10.15

Overview of the project and its general status




TOP

SPEC



Background



"Next generation precision antibody profiling – from science fiction to reality"



- **Vision:** diseases are cured by body's own immune system.
- **Challenge:** cost of developing targeted immunotherapies.
- **Ultimate aim:** Reducing time/cost of novel immunotherapies.
- **Obstacle:** Understanding how antibodies are produced in humans.
- **Antibodies:** macro-proteins (130-1000 kDa) binding to targets (antigens) via variable sequences. Astronomical number of sequences exist theoretically, but tiny fraction of all possible sequences are actually generated and selected.
- **Specific aim:** sequencing antibody repertoire and correlating it with disease/antigen to understand the rules of production/selection.

TopSpec's solution to this challenge: top-down mass spectrometry sequencing platform

Characterization of Antibodies

Why Antibodies ?

Immunotherapy

Biotherapeutics & Biosimilars
(mAbs, ADC)

Medical Diagnostics (ELISA)

Life Sciences R&D


Why Top-Down ?

Degradation products – (DE,PR)

Proteoform Characterization
(SS scrambling, Glycans) – (DI, DE, PR)

Structural Characterization – (DI, DE,PR)

mAb Design & *De Novo* sequencing – (DI)



Pharma - Biologics

Discovery



DEvelopment



PRoduction



Market

Sequencing of Antibodies

State-of-the-art Limitations


Bottom-Up Protein ID & *de novo* sequencing

Sub-optimal for determining modification occupancy

Proteoforms are not accessible


Speed & Accuracy

Identification & sequencing of multiple proteins (mAbs) with unknown sequence simultaneously from a complex sample is not possible in bottom-up.



Top-Down *de-novo* sequencing of proteins from complex samples is feasible

TopSpec Platform



We are enabling the future of antibody characterization

We envision:

- ◆ **Analysis of complex samples** – *de novo* sequencing of antibodies at proteoform level in complex samples with top-down analysis. The current state-of-the-art is limited to 3-5 mAbs in a mixture
- ◆ **Improvements in reliability/speed/cost** – Today *de novo* sequencing is time consuming and expensive - reducing analysis time and cost is a major step forward


TopSpec Innovations

- ◆ Novel hardware to isolate antibodies and analyze their ions in the gas phase
- ◆ Novel ion activation techniques & methods in tandem MS
- ◆ Novel signal processing in Fourier transform MS
- ◆ Novel data analysis algorithms for top-down sequencing



Top Down Sequencing of Antibodies

State-of-the-Art



Fragments are mainly localized:

- in the variable region of light and heavy chains
- between variable and constant domains in both chains
- between heavy chain constant domains C_H2 and C_H3
- In the S-S linked heavy chain constant domain C_H3

```

1 · D · I · Q · M · T · Q · S · P · S · L · S · A · S · V · G · D · R · V · T · I · T · C · R · A · 25
26 · S · Q · D · V · G · I · Y · V · N · W · F · Q · K · P · G · K · A · P · K · R · L · Y · R · 50
51 · A · T · N · L · A · D · G · V · P · S · R · F · S · G · S · R · S · G · I · T · D · F · T · L · T · I · 75
76 · S · S · L · Q · P · E · D · F · A · T · Y · Y · C · L · E · F · D · E · H · P · L · T · F · G · G · 100
101 · G · T · K · V · E · I · K · R · T · V · A · A · P · S · V · F · L · F · P · P · S · D · E · Q · L · 125
126 · K · S · G · T · A · S · V · V · C · L · L · N · N · F · Y · P · R · E · A · K · V · Q · W · K · V · 150
151 · D · N · A · L · Q · S · G · N · Q · E · S · V · T · E · Q · D · L · S · K · D · S · T · Y · S · L · 175
176 · S · S · T · L · T · L · S · K · A · D · Y · E · K · H · K · V · Y · A · C · E · V · T · H · Q · G · 200
201 · L · S · S · P · V · T · K · S · F · N · R · G · E · C · 214
    
```

32% Sequence Coverage



```

1 · E · V · Q · L · V · E · S · G · G · L · V · Q · P · G · G · S · L · R · L · S · C · A · A · S · 25
26 · G · F · T · F · N · N · Y · W · M · T · W · V · R · Q · A · P · G · K · G · L · E · W · V · A · S · 50
51 · I · D · N · S · G · D · N · T · Y · Y · P · D · S · V · K · D · R · F · T · I · S · R · D · N · A · 75
76 · K · N · S · L · Y · L · Q · M · N · S · L · R · A · E · D · T · A · V · Y · Y · C · A · R · G · G · 100
101 · D · I · T · T · G · F · D · Y · W · G · Q · G · T · L · V · T · V · S · S · A · S · T · K · G · P · 125
126 · S · V · F · P · L · A · P · S · S · K · S · T · S · G · G · T · A · A · L · G · C · L · V · K · D · 150
151 · Y · F · P · E · P · V · T · V · S · W · N · S · G · A · L · T · S · G · V · H · T · F · P · A · V · 175
176 · L · Q · S · S · G · L · Y · S · L · S · S · V · V · T · V · P · S · S · S · L · G · T · Q · T · Y · 200
201 · I · C · N · V · N · H · K · P · S · N · T · K · V · D · K · K · V · E · P · K · S · C · D · K · T · 225
226 · H · T · C · P · P · C · P · A · P · E · A · A · G · A · P · S · V · F · L · F · P · P · K · P · K · 250
251 · D · T · L · M · I · S · R · T · P · E · V · T · C · V · V · V · D · V · S · H · E · D · P · E · V · 275
276 · K · F · N · W · Y · V · D · G · V · E · V · H · N · A · K · T · K · P · R · E · E · Q · Y · N · S · 300
301 · T · Y · R · V · V · S · V · L · T · V · L · H · Q · D · W · L · N · G · K · E · Y · K · C · K · V · 325
326 · S · N · K · A · L · P · A · P · I · E · K · T · I · S · K · A · K · G · Q · P · R · E · P · Q · V · 350
351 · Y · T · L · P · P · S · R · E · E · M · T · K · N · Q · V · S · L · T · C · L · V · K · G · F · Y · 375
376 · P · S · D · I · A · V · E · W · E · S · N · G · Q · P · E · N · N · Y · K · T · T · P · P · V · L · 400
401 · D · S · D · G · S · F · F · L · Y · S · K · L · T · V · D · K · S · R · W · Q · Q · G · N · V · F · 425
426 · S · C · S · V · M · H · E · A · L · H · N · H · Y · T · Q · K · S · L · S · L · S · P · G · 448
    
```

35% Sequence Coverage




Middle Down Sequencing of Antibodies

State-of-the-Art



Middle Down Sequencing of mAbs: Light and Heavy Chain Pairing (50 kDa)

State-of-the-Art



Data processing approach	LC runs	Sequence coverage, %	
		Light Chain	Heavy Chain
Transient	10	34.0	41.9

TopSpec Platform


fasmatech

ThermoFisher
SCIENTIFIC

ion mobility spectrometer

omnitrapp

orbitrap q exactive hf x




amino-acid sequence

1) QVQIYQGGHAYVQVFFK 433
31) QVQIYQGGHAYVQVFFK 433
51) AQKFGGAYVQVFFK 433
71) TAVVYCARSPFPYVDSGGYYPGADQW 395
91) QCTHVTSSASVAAFPVFIFPPSDQLKES 343
111) IASVYVQIYQVFP AKVQKVDNSA QUGR 293
131) SQEVTTEQDSKSTYSLSSTLTLEKADPLEK 253
151) HLYVYAGVQVFFK 433
171) QCTHVTSSASVAAFPVFIFPPSDQLKES 343
191) HLYVYAGVQVFFK 433
211) HRAKTKPPELQVNSYRYVSVLHLHQDL 133
231) NCKEYKCKVSNCALPAPCEKTSIAKQQR 129
251) FPGVYVQIYQVFP AKVQKVDNSA QUGR 293
271) SDCAVEWCSNSQPENNYKTTTPVLDSQGLF 123
291) HLYVYAGVQVFFK 433
311) HLYVYAGVQVFFK 433


NOTTINGHAM
TRENT UNIVERSITY

ftms booster



Spectroswiss


biomotif



Karolinska
Institutet

protein
extract

Institut Pasteur




MSVision

TopSpec Work Packages

- WP1 Omnitrap development and testing → FT, TF: **3 deliverables**
- WP2 Implementation of CAD, ECD, HECD, UV, IR, PD, and EID MS/MS techniques in Omnitrap → KI, FT, TF, TNTU, IP: **3 deliverables**
- WP3 Development and application of H-atom bombardment (HAB MS/MS techniques) → FT, KI, TF, TNTU, IP: **2 deliverables**
- WP4 Development and application of Coulomb explosion MS/MS technique → KI, FT, B, TNTU, IP: **2 deliverables**
- WP5 Development of pl-Trap-ESI combination → B, KI, TF, TNTU, IP, MV: **2 deliverables**
- WP6 Modification of the Orbitrap mass spectrometer → TF, KI: **2 deliverables**
- WP7 Signal detection and data processing → S, KI, FT, TNTU, IP: **3 deliverables**
- WP8 Dissemination, Communication & Exploitation → MV, KI, FT, TF, S, B, TNTU, IP: **8 deliverables**
- WP9 Project Management and Administration → KI, FT, TF, S, B, TNTU, IP MV: **4 deliverables**


TopSpec Deliverables & Milestones




Milestones:T2/T5. Omnitrap & IMS Electronics design (FT, Dec 31, 2019)



Omnitrap QExactive™ HF



Omnitrap Exploris™ 480




Precursor Omnitrap

- Designed ✓
- Installed ✓
- Tested ✓
- Revisions ✓

Precursor IM drift cell


- Designed ✓
- Tested ✓
- Revisions ✓

IMS configuration




Milestone: T1.2 – T1.5. Omnitrap & IMS Electronics design (FT, Dec 31, 2019)

Omnitrap Instrumentation Development Overview



TopSpec Deliverables & Milestones



Deliverable: D6.1. Installation of QE for Omnitrap development (FT, Dec 31, 2019)




QExactive™ HF Mass Spec installed in Athens (Sept 2019)

HCD External Instrument Mode *	On
<input checked="" type="checkbox"/> Emeter/CTCD	
Averaging	0
<input checked="" type="checkbox"/> Processing	
<input checked="" type="checkbox"/> Ion transfer	
<input type="checkbox"/> HCD event	
HCD Time * (ms)	20
Purge Time * (ms)	5.0
HCD Field Gradient --- Purge * (V)	20.0
Ext. Instr. Mode - HCD Offset to External...	11
Ext. Instr. Mode - HCD Offset from External...	3
Ext. Instr. Mode - HCD Gradient to External...	-50
Ext. Instr. Mode - HCD Gradient from External...	25
Ext. Instr. Mode - HCD and C-Trap exit lens...	35
Ext. Instr. Mode - HCD exit lens open to...	25
Ext. Instr. Mode - HCD exit lens open from...	-25
Ext. Instr. Mode - HCD ion transfer* (ms)	50
Ext. Instr. Mode - HCD Waiting for External...	100
HCD Exit Lens Trigger Voltage low* (V)	35
HCD Exit Lens Trigger Voltage high* (V)	-35
Intact Protein mode	Off
HMR mode	On
Trapping gas pressure setting *	Override: 0
Spectrum data type	Profile
C-Trap Charge Detector Support *	On

Tune s/w modifications ✓

Debugging ✓


TopSpec Deliverables & Milestones




Milestone: T7.1. Demonstrated ion isotopic distribution deconvolution (SPS, Dec 31, 2019)

Hypothesis: Information on product ion signal decay rate could help deconvolve complex top-down spectra

Milestone M1: mobility-like resolution of ~ 7.1 is achieved, further improvements are being researched



TopSpec Deliverables & Milestones



Deliverable: D8.1 IP protection strategy (MSV, Mar 31, 2019)



TopSpec

Project Deliverable Report

D8.1 TopSpec Intellectual Property Protection Strategy

Version: 1.2

Author: Jan Commandeur (MS)

Contributors: -

Internal reviewers: -

Deliverable due date: 2019-04-01

Actual submission date:

Work package: WP8

Task: T8.5

Dissemination level: Confidential (CO)*

Lead beneficiary: MS

Status: Progress

D8.1 IP protection strategy

Created	✓
Reviewed	✓
Submitted	✓

Covers:

- IP Strategy and Policy
- Use and ownership IP
- Background / foreground IP
- IP Asset Register

Deliverable: D8.2: Draft Exploitation plan & Business strategy (MSV, Dec 31, 2019)



TopSpec
Project Deliverable Report

D8.2 Draft Exploitation and Dissemination Plan

Version:	1.1
Author:	Remco Swart (MS)
Contributors:	Susanna Lundström (KI), Jan Commandeur (MS)
Internal reviewers:	-
Deliverable due date:	2019-12-31
Actual submission date:	2019-12-19
Work package:	WP8
Task:	T8.2
Dissemination level:	Public
Lead beneficiary:	MS
Status:	Progress


D8.2 Draft Exploitation plan & business strategy

Created ✓
Reviewed ✓
Submitted ✓

Covers:

- Tools for tracking activities
- Marketing collaterals
- Social media communication
- Meetings and conferences
- Interaction with partners
- Connect with potential users
- Exploitation of results

TopSpec Deliverables & Milestones



Deliverable


D9.1 Logo and Website launch and public accessibility (KI, Feb 28, 2019)

Logo:



Website: <https://topspec.ki.se>

Deliverable D9.2 Data Management Plan (KI, June 30, 2019)



Summary:

All deliverables and milestones have been reached by the TopSpec Consortium in full and in time


Prospects for 2020-2021

- No major deviation from the working plan content is foreseen
- No major deviation from the time schedule is foreseen

Unplanned findings useful for TopSpec

- Tandem pl-fractionation promises higher resolution in shorter time
- Deconvolution based on transient decay seems to exceed expectations, reaching the resolution 6-7 instead of 2-3.

TopSpec Deliverables & Milestones



TopSpec Deliverables & Milestones

